Literature DB >> 20454883

[Use of botulinum toxin in ORL departments in Germany].

P Matthes1, J Kruegel, C Karapantzou, J Winterhoff, R Laskawi.   

Abstract

BACKGROUND: There are no regional data about the prevalence and use of botulinum toxin (BoNT) in otorhinolaryngology (ORL) departments in Germany. In order to obtain an overview of the current applications of BoNT in ORL departments a survey was carried out.
MATERIALS AND METHODS: Standardized multi-choice questionnaires were mailed to 150 ORL departments. In the analysis a differentiation was made between university and regional departments. Also an analysis of the whole collective of respondent hospitals was carried out. The most commonly treated indication is the Frey syndrome followed by hypersalivation due to a salivary fistula after parotidectomy, dysphagia, aesthetic application and laryngeal dystonia.
RESULTS: The rate of return was 62% and 75% of all responding hospitals use BoNT as a therapeutic option, especially where "off-label-use" indications are concerned (15 out of 20 indications or 75%). DISCUSSION: BoNT is widely used as a therapeutic option with an increasing trend. Due to different applications a schedule of hospitals would be helpful in order to be able to find the nearest hospital for the appropriate indications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20454883     DOI: 10.1007/s00106-009-2056-3

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  7 in total

Review 1.  Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases.

Authors:  S Jitpimolmard; S Tiamkao; M Laopaiboon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

2.  [Therapeutic use of botulinum toxin in otorhinolaryngology. 1: Treatment of movement disorders of mimetic muscles].

Authors:  R Laskawi
Journal:  HNO       Date:  1998-03       Impact factor: 1.284

Review 3.  Botulinum toxin: basic science and clinical uses in otolaryngology.

Authors:  A Blitzer; L Sulica
Journal:  Laryngoscope       Date:  2001-02       Impact factor: 3.325

4.  Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study.

Authors:  Holger G Gassner; Anthony E Brissett; Clark C Otley; Derek K Boahene; Andy J Boggust; Amy L Weaver; David A Sherris
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

5.  A long-term follow-up of botulinum toxin A in cervical dystonia.

Authors:  B Mohammadi; N Buhr; H Bigalke; K Krampfl; R Dengler; K Kollewe
Journal:  Neurol Res       Date:  2009-03-11       Impact factor: 2.448

Review 6.  [Botulinum toxin in otorhinolaryngology].

Authors:  S Rohrbach; R Laskawi
Journal:  HNO       Date:  2004-07       Impact factor: 1.284

7.  Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.

Authors:  Samih Badarny; Zvi Susel; Silvia Honigman
Journal:  Isr Med Assoc J       Date:  2008-07       Impact factor: 0.892

  7 in total
  5 in total

1.  [Botulinum toxin in the head and neck region].

Authors:  R Laskawi
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

2.  [Botulinum toxin for the treatment of secretory disorders of the head and neck area].

Authors:  A Steffen
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

3.  [Botulinum toxin to treat sweat caused sequelae in patients with hearing aids, active middle ear implants and cochlear implants].

Authors:  R Laskawi; J Winterhoff; J Blum; C Matthias
Journal:  HNO       Date:  2012-11       Impact factor: 1.284

Review 4.  [Botulinum toxin in otorhinolaryngology - an update].

Authors:  R Laskawi; A Olthoff
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

5.  Botulinum toxin treatment of salivary fistulas following parotidectomy: follow-up results.

Authors:  Rainer Laskawi; Jan Winterhoff; Sabrina Köhler; Laura Kottwitz; Christoph Matthias
Journal:  Oral Maxillofac Surg       Date:  2012-11-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.